Advertisement

Topics

Pfizer's Xalkori sees rejection at the hands of NICE in lung cancer

04:17 EST 19 Jan 2018 | Pharmafile

UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the treatment of ROS1-positive advanced non-small cell lung cancer (NSCLC) in both previously treated patients and those yet to receive treatment, asserting that the drug could not be considered value for money.

read more

Original Article: Pfizer's Xalkori sees rejection at the hands of NICE in lung cancer

NEXT ARTICLE

More From BioPortfolio on "Pfizer's Xalkori sees rejection at the hands of NICE in lung cancer"

Quick Search
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...